Kamban Hirasen
Overview
Explore the profile of Kamban Hirasen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hendrickson C, Hirasen K, Mongwenyana C, Benade M, Bothma R, Smith C, et al.
Lancet HIV
. 2025 Feb;
12(2):e130-e142.
PMID: 39914894
Background: Despite several service delivery models that aim to improve uptake and persistence of pre-exposure prophylaxis (PrEP) in sub-Saharan Africa, the full costs of daily oral PrEP provision in routine...
2.
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, Conradie F, et al.
PLoS One
. 2024 Oct;
19(10):e0309034.
PMID: 39432463
Background: Drug-resistant (DR) tuberculosis (TB) is typically characterized by resistance to a single or combination of first- and/or second-line anti-TB agents and commonly includes rifampicin-resistant (RR)-TB, multidrug-resistant (MDR)-TB, pre-extensively drug-resistant...
3.
Hendrickson C, Hirasen K, Mongwenyana C, Benade M, Bothma R, Smith C, et al.
medRxiv
. 2023 Aug;
PMID: 37645864
Background: Oral pre-exposure prophylaxis (PrEP) is a highly efficacious biomedical HIV prevention tool, yet despite being recommended by the World Health Organization (WHO) since 2015, uptake and persistence remain limited...
4.
Huber A, Hirasen K, Brennan A, Phiri B, Tcherini T, Mulenga L, et al.
Gates Open Res
. 2023 May;
7:42.
PMID: 37153118
Since 2017 global guidelines have recommended "same-day initiation" (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a...
5.
Bor J, Kluberg S, LaValley M, Evans D, Hirasen K, Maskew M, et al.
Am J Epidemiol
. 2022 Jan;
191(6):999-1008.
PMID: 35081613
Simplified drug regimens may improve retention in care for persons with chronic diseases. In April 2013, South Africa adopted a once-daily single-pill human immunodeficiency virus (HIV) treatment regimen as the...
6.
Hirasen K, Fox M, Hendrickson C, Sineke T, Onoya D
Ther Clin Risk Manag
. 2020 Mar;
16:169-180.
PMID: 32184609
Introduction: Officially rolled out on 01 September 2016, South Africa's Universal Test and Treat (UTT) policy calls for first-line antiretroviral treatment (ART) initiation among all known HIV-positive patients, irrespective of...
7.
Hirasen K, Evans D, Jinga N, Grabe R, Turner J, Mashamaite S, et al.
Patient Prefer Adherence
. 2020 Feb;
14:133-151.
PMID: 32021124
Introduction: The best method to measure adherence to antiretroviral therapy (ART) in resource-limited settings has not yet been established, particularly among adolescents and young adults (AYAs). The use of mobile...
8.
van Rensburg C, Berhanu R, Hirasen K, Evans D, Rosen S, Long L
PLoS One
. 2019 Jun;
14(6):e0217820.
PMID: 31170207
Background: Drug resistant-tuberculosis is a growing burden on the South African health care budget. In response the National Department of Health implemented two important strategies in 2011; universal access to...
9.
Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L
PLoS One
. 2018 Oct;
13(10):e0205463.
PMID: 30300403
Introduction: Treatment success rates of rifampicin resistant (RR)/multi-drug resistant (MDR) tuberculosis (TB) in South Africa range from 43-48%, falling short of the World Health Organization's target of ≥75%. We present...
10.
Shearer K, Evans D, Xhosa B, Hirasen K, Bracken C, Mahomed K, et al.
PLoS One
. 2018 Sep;
13(9):e0203797.
PMID: 30252844
Background: Depression is a leading cause of disability and may be associated with decreased adherence to ART. We sought to describe the prevalence of depressive symptoms and outcomes one year...